Associate Professor of Medicine, Beth Israel Deaconess Medical Center
Oncology
Dr. James W. Mier, MD
|
|
Give Review
James W. Mier, MD practices Oncology. He went to medical school at Indiana University School of Medicine. Indiana University School of Medicine is ranked 45/47 in Research/PrimaryCare. Doctor James W. Mier, MD is a published MD as well. He has 29 publications published. The latest was: Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. He accepts all Medicare patients.
Publications
- Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.
- The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma.
- Clinical utility of a blood-based BRAF V600E mutation assay in Melanoma.
- PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma Cells.
- Cox-2 inhibition enhances the activity of sunitinib in human renal Cell carcinoma xenografts.
- Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma.
- A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas.
- Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell Cancer.
- Resistance of renal Cell carcinoma to sorafenib is mediated by potentially reversible gene expression.
- Renal Cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling.
- The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal Cell carcinoma.
- Innovations and challenges in renal Cancer: summary statement from the Third Cambridge Conference.
- Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal Cell carcinoma.
- GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma Cell lines.
- The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal Cancer.
- Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced Cancer.
- Innovations and challenges in Melanoma: summary statement from the first Cambridge conference.
- Targeting the mitogen-activated protein kinase pathway in the treatment of Malignant melanoma.
- The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma Cells.
- Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal Cell carcinoma.
- Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial Cells.
- Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal Cell carcinoma.
- Biological drug duo deLivers one-two tumor punch.
- Overexpression of kinase suppressor of Ras upregulates the high-molecular-weight tropomyosin isoforms in ras-transformed NIH 3T3 fibroblasts.
- Immunotherapy With Low-Dose IL-2 in Combination With GM-CSF.
- A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic Melanoma.
- Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics.
- Assaying for BRAF V600E in Tissue and Blood in Melanoma.
Schools
Indiana University School Of Medicine
Emory Affil Hosps
Nci
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Indiana University School of Medicine
Hospital
-
Beth Israel Deaconess Medical Center
Drug Facts
| NPI NUMBER | 1265464788 | |
| NPPES Provider LastName | MIER | |
| NPPES Provider FirstName | JAMES | |
| NPPES Provider ZIPCode | 02215 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 31.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1265464788 |
| Last Name Of The Provider | MIER |
| First Name Of The Provider | JAMES |
| View All |
Similar Doctors
|
|
Dr. Othon Iliopoulos, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark M. Awad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam B. Lerner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marc B. Garnick, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mark S. Huberman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin Chin, MD
This Doctor is OpenDoctor Recommended.
|